473 related articles for article (PubMed ID: 33666903)
1. Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond.
Barroso-Sousa R; Tolaney SM
BioDrugs; 2021 Mar; 35(2):159-174. PubMed ID: 33666903
[TBL] [Abstract][Full Text] [Related]
2. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates for Breast Cancer.
Marmé F
Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates in Triple Negative Breast Cancer.
Keskinkilic M; Sacks R
Clin Breast Cancer; 2024 Apr; 24(3):163-174. PubMed ID: 38341370
[TBL] [Abstract][Full Text] [Related]
5. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
6. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
Fenton MA; Tarantino P; Graff SL
Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
[TBL] [Abstract][Full Text] [Related]
7. Unveiling the antibody-drug conjugates portfolio in battling Triple-negative breast cancer: Therapeutic trends and Future horizon.
Khadela A; Soni S; Shah AC; Pandya AJ; Megha K; Kothari N; Cb A
Med Oncol; 2022 Dec; 40(1):25. PubMed ID: 36456774
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy.
Jeong JH; Kim SB
Breast; 2022 Dec; 66():199-203. PubMed ID: 36327625
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug Conjugates for the Treatment of Breast Cancer.
Corti C; Giugliano F; Nicolò E; Ascione L; Curigliano G
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34207890
[TBL] [Abstract][Full Text] [Related]
10. Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer.
Abelman RO; Keenan JC; Ryan PK; Spring LM; Bardia A
Hematol Oncol Clin North Am; 2023 Feb; 37(1):151-167. PubMed ID: 36435607
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond-A 2023 Review.
Xiao T; Ali S; Mata DGMM; Lohmann AE; Blanchette PS
Curr Oncol; 2023 Jul; 30(7):6447-6461. PubMed ID: 37504334
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
Shastry M; Jacob S; Rugo HS; Hamilton E
Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
[TBL] [Abstract][Full Text] [Related]
13. Antibody-Drug Conjugate Revolution in Breast Cancer: The Road Ahead.
Grinda T; Rassy E; Pistilli B
Curr Treat Options Oncol; 2023 May; 24(5):442-465. PubMed ID: 36966267
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug Conjugates for Breast Cancer Treatment.
Sheikh MS; Huang Y
Recent Pat Anticancer Drug Discov; 2022; 18(2):108-113. PubMed ID: 35909271
[TBL] [Abstract][Full Text] [Related]
15. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
Nicolò E; Zagami P; Curigliano G
Curr Opin Oncol; 2020 Sep; 32(5):494-502. PubMed ID: 32657795
[TBL] [Abstract][Full Text] [Related]
16. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.
Saini KS; Punie K; Twelves C; Bortini S; de Azambuja E; Anderson S; Criscitiello C; Awada A; Loi S
Expert Opin Biol Ther; 2021 Jul; 21(7):945-962. PubMed ID: 34043927
[TBL] [Abstract][Full Text] [Related]
17. Payload diversification: a key step in the development of antibody-drug conjugates.
Conilh L; Sadilkova L; Viricel W; Dumontet C
J Hematol Oncol; 2023 Jan; 16(1):3. PubMed ID: 36650546
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review.
Pondé N; Aftimos P; Piccart M
Curr Treat Options Oncol; 2019 Apr; 20(5):37. PubMed ID: 30931493
[TBL] [Abstract][Full Text] [Related]
19. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Resistance to Antibody-Drug Conjugates.
Khoury R; Saleh K; Khalife N; Saleh M; Chahine C; Ibrahim R; Lecesne A
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
